Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
复制标题
DOI：
10.1016/j.canep.2022.102203
复制
发表时间：
2022-08
影响因子：
2.6
通讯作者：
McMahon, Catherine M.
中科院分区：
文献类型：
--
作者：
Dillard, Lauren K.;Lopez-Perez, Lucero;Martinez, Ricardo X.;Fullerton, Amanda M.;Chadha, Shelly;McMahon, Catherine M.
铂类化疗药物顺铂和卡铂在全球范围内广泛用于癌症治疗，可能导致耳毒性听力损失。铂基化合物的高癌症发病率和显着的耳毒性作用对全球公共健康构成威胁。这项研究的目的是双重的。首先，通过系统评价和荟萃分析来估计与顺铂和/或卡铂治疗相关的耳毒性听力损失的患病率。其次，估计与顺铂和/或卡铂暴露相关的耳毒性听力损失的年度全球负担。为了进行系统评价，检索了三个数据库（Ovid Medline、Ovid Embase 和 Web of Science 核心合集），并纳入了报告癌症患者中客观测量的耳毒性听力损失患病率的研究。随机效应荟萃分析确定了耳毒性听力损失的总体患病率（95% 置信区间 [CI]），并根据治疗和患者属性对估计值进行了分层。耳毒性听力损失负担的估计是根据已发表的对经常使用铂类化合物治疗的癌症发生率的全球估计和癌症特异性治疗率得出的。荟萃分析中纳入了 87 条记录（n = 5077 人）。与顺铂和/或卡铂暴露相关的耳毒性听力损失的汇总患病率为 43.17% [CI 37.93–48.56%]。涉及顺铂的治疗方案（仅顺铂：49.21% [CI 42.62–55.82%]；顺铂和卡铂：56.05% [CI 45.12–66.43%]）与仅卡铂治疗方案（13.47% [CI 8.68–20.32%]）相比，患病率估计较高。我们对负担的粗略估计表明，全世界大约有 100 万人可能接触顺铂和/或卡铂，这将导致全球每年近 50 万例听力损失病例。迫切需要减少耳毒性对癌症患者的影响。这可以通过实施专注于一级、二级和三级听力损失预防的现有策略来部分实现。通过耳保护剂预防初级耳毒性应成为研究和政策的优先事项。据估计，每年有一百万人接触化疗药物。据估计，每年有 50 万例听力损失病例是由化疗引起的。接触顺铂和/或卡铂后听力损失发生率为 43%。应优先考虑听力损失的一级、二级和三级预防。预防耳毒性听力损失是全球公共卫生的首要任务。
Platinum-based chemotherapeutic agents cisplatin and carboplatin are widely used in cancer treatment worldwide and may result in ototoxic hearing loss. The high incidence of cancer and salient ototoxic effects of platinum-based compounds pose a global public health threat. The purpose of this study was twofold. First, to estimate the prevalence of ototoxic hearing loss associated with treatment with cisplatin and/or carboplatin via a systematic review and meta-analysis. Second, to estimate the annual global burden of ototoxic hearing loss associated with exposure to cisplatin and/or carboplatin. For the systematic review, three databases were searched (Ovid Medline, Ovid Embase, and Web of Science Core Collection) and studies that reported prevalence of objectively measured ototoxic hearing loss in cancer patients were included. A random effects meta-analysis determined pooled prevalence (95% confidence intervals [CI]) of ototoxic hearing loss overall, and estimates were stratified by treatment and patient attributes. Estimates of ototoxic hearing loss burden were created with published global estimates of incident cancers often treated with platinum-based compounds and cancer-specific treatment rates. Eighty-seven records (n = 5077 individuals) were included in the meta-analysis. Pooled prevalence of ototoxic hearing loss associated with cisplatin and/or carboplatin exposure was 43.17% [CI 37.93–48.56%]. Prevalence estimates were higher for regimens involving cisplatin (cisplatin only: 49.21% [CI 42.62–55.82%]; cisplatin & carboplatin: 56.05% [CI 45.12–66.43%]) versus carboplatin only (13.47% [CI 8.68–20.32%]). Our crude estimates of burden indicated approximately one million individuals worldwide are likely exposed to cisplatin and/or carboplatin, which would result in almost half a million cases of hearing loss per year, globally. There is an urgent need to reduce impacts of ototoxicity in cancer patients. This can be partially achieved by implementing existing strategies focused on primary, secondary, and tertiary hearing loss prevention. Primary ototoxicity prevention via otoprotectants should be a research and policy priority. An estimated one million people are exposed to chemotherapeutic drugs per year. An estimated half a million cases of hearing loss per year are from chemotherapy. Hearing loss prevalence after exposure to cisplatin and/or carboplatin is 43%. Primary, secondary and tertiary prevention of hearing loss should be prioritized. Ototoxic hearing loss prevention is a global public health priority.
登录
查看更多内容
DOI：
10.1016/j.ijrobp.2008.07.034
发表时间：
2009-04-01
影响因子：
7
作者：
Chan, S. H.;Ng, W. T.;Chow, S. K.
通讯作者：
Chow, S. K.
影响因子：
1.6
作者：
Bhagat S;Bass J;Qaddoumi I;Brennan R;Wilson M;Wu J;Galindo CR;Paglialonga A;Tognola G
通讯作者：
Tognola G
影响因子：
1
作者：
Arora, R.;Thakur, J. S.;Seam, R. K.
通讯作者：
Seam, R. K.
影响因子：
3.2
作者：
Abujamra, Ana Lucia;Escosteguy, Juliana Ribas;Gregianin, Lauro Jose
通讯作者：
Gregianin, Lauro Jose
影响因子：
6.2
作者：
Brinkman TM;Bass JK;Li Z;Ness KK;Gajjar A;Pappo AS;Armstrong GT;Merchant TE;Srivastava DK;Robison LL;Hudson MM;Gurney JG
通讯作者：
Gurney JG